Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

MorphoSys AG : MorphoSys Announces Clinical Milestone in Ophthalmology Program



MorphoSys AG : MorphoSys Announces Clinical Milestone in Ophthalmology Program

MorphoSys AG / MorphoSys Announces Clinical Milestone in Ophthalmology Program
. Processed and transmitted by Thomson Reuters ONE. The issuer is solely
responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that
it has received a milestone payment from Novartis in connection with the
clinical trial application (CTA/IND) and projected initiation of a Phase 1
clinical trial. The HuCAL-derived, fully human antibody will be developed in
the therapeutic area of ophthalmology.
"Our pipeline of therapeutic antibody candidates is more advanced than ever.
Today's news marks the first of up to five clinical milestones from our
collaborators that we expect to see during the course of the year," commented
Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "In total, our
collaboration with Novartis has resulted in seven clinical programs to date,
three currently being in Phase 1 and four in Phase 2."

Current Status of MorphoSys's Pipeline:
In total, MorphoSys's pipeline now comprises 21 clinical programs. Of these,
17 are partnered programs, of which nine are in Phase 1, seven are in Phase 2
and one is in Phase 2/3 development. The remaining four are the Company's
proprietary programs MOR103, which has concluded a Phase 1b/2a trial for
rheumatoid arthritis and is currently being evaluated in a Phase 1b trial in
multiple sclerosis; MOR208, which has concluded a Phase 1 trial for chronic
lymphocytic leukemia and will be evaluated in Phase 2 trials in B-ALL and NHL;
and MOR202, which is in a Phase 1/2a trial for multiple myeloma.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
With its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys
is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
updates about MorphoSys, visit http://www.morphosys.com

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® and
Ylanthia® and 100 billion high potentials® are registered trademarks of
MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.

For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com

Media Release (PDF)

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE
HUG#1697992

--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All
Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement